At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
HIZENTRA ®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
In Brief
A Phase 2 clinical trial evaluating HIZENTRA ® for Myasthenia Gravis. Completed, enrolled 23 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis
CountriesCanada, United States
CollaboratorsCSL Behring
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2015
Primary CompletionNov 2017
Study CompletionJan 2018
TodayJul 2026
First PostedApr 1, 2014
Enrollment StartMay 1, 2015
Primary CompletionNov 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.3 years ago
Interventions
HIZENTRA ®drug
Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.